Sarepta Therapeutics' (SRPT) Buy Rating Reiterated at Guggenheim

Key Points

• Guggenheim has reiterated a "buy" rating for Sarepta Therapeutics (SRPT) with a price target of $22.00, suggesting a potential upside of 26.51% from its current trading price.
• Sarepta's recent earnings report showed significant growth, with a 68.4% increase in revenue year-over-year and an earnings per share (EPS) of $2.02, surpassing estimates.
• The stock has a wide range of ratings from analysts, with 8 showing a "buy," 15 a "hold," and 6 a "sell," leading to a current consensus rating of "hold" with an average target price of $39.32.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "buy" rating restated by equities researchers at Guggenheim in a research note issued to investors on Monday,Benzinga reports. They currently have a $22.00 price objective on the biotechnology company's stock. Guggenheim's price objective would indicate a potential upside of 26.51% from the stock's current price.

Other equities analysts also recently issued research reports about the stock. TD Cowen downgraded shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price objective for the company. in a report on Wednesday, June 18th. HC Wainwright reaffirmed a "sell" rating on shares of Sarepta Therapeutics in a report on Monday, August 25th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Sarepta Therapeutics in a report on Monday, June 16th. Leerink Partners raised their target price on Sarepta Therapeutics from $12.00 to $15.00 and gave the company a "market perform" rating in a research note on Tuesday, September 9th. Finally, JPMorgan Chase & Co. upgraded Sarepta Therapeutics from an "underweight" rating to a "neutral" rating and set a $24.00 target price on the stock in a research note on Tuesday, July 29th. Eight research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat, Sarepta Therapeutics currently has a consensus rating of "Hold" and an average target price of $39.32.

Sarepta Therapeutics Trading Down 2.9%

Shares of SRPT stock opened at $17.39 on Monday. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $138.81. The firm's 50-day simple moving average is $17.75 and its 200-day simple moving average is $40.39. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The firm has a market cap of $1.70 billion, a P/E ratio of -19.99 and a beta of 0.49.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company had revenue of $611.09 million during the quarter, compared to the consensus estimate of $530.66 million. During the same quarter last year, the company earned $0.07 earnings per share. Sarepta Therapeutics's revenue for the quarter was up 68.4% on a year-over-year basis. As a group, equities analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Byrne Asset Management LLC bought a new stake in Sarepta Therapeutics during the first quarter worth approximately $30,000. Center for Financial Planning Inc. acquired a new stake in Sarepta Therapeutics in the 1st quarter worth $31,000. Ancora Advisors LLC increased its holdings in shares of Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 300 shares during the period. Pandora Wealth Inc. bought a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $45,000. Finally, Brooklyn Investment Group lifted its stake in shares of Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company's stock valued at $46,000 after buying an additional 590 shares during the period. Institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.